Aurinia pharmaceuticals inc.AUPH.US Overview

US StockHealthcare

(No presentation for AUPH)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

AUPH Overall Performance

AUPH AI Analysis & Strategy

AUPH Recent Performance

0.06%

Aurinia pharmaceuticals inc.

0.81%

Avg of Sector

-1.14%

S&P500

AUPH PowerScanner

AUPH Key Information

AUPH Valuation Metrics

AUPH Earnings Table

AUPH Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.